Liquid biopsies have shown promise for predicting clinical outcomes. Shu Xia, from the Huazhong University of Science and Technology and the Medical College of Wisconsin, and others recently published their research evaluating tumor-associated genomic and genetic variations in plasma cell-free DNA (cfDNA) and their associations with treatment response and overall patient survival.

Drs. Xia and others used the NEXTflex DNA Sequencing Kit and NEXTflex DNA Barcodes to construct libraries from cell free DNA obtained from 20 patients with advanced prostate cancer for whole genome and targeted sequencing. Read our latest featured publication to learn more about their research.